10-Q: Apellis Pharmaceuticals Reports Q1 2025 Financial Results: SYFOVRE Sales Dip Amidst Increased Rebates, EMPAVELI Faces Oral Competition

Apellis Pharmaceuticals' Q1 2025 results reveal a decrease in SYFOVRE sales due to higher rebates and EMPAVELI revenue decline due to oral competition, despite progress in clinical trials and regulatory submissions.

Summary

• Apellis Pharmaceuticals reported a net loss of $92.2 million for Q1 2025, compared to a net loss of $66.4 million in Q1 2024.
• Total revenue decreased by 3% to $166.8 million in Q1 2025 from $172.3 million in Q1 2024.
• SYFOVRE net product revenue was $130.2 million in Q1 2025, a decrease from $137.5 million in Q1 2024, primarily due to increased rebates.
• EMPAVELI net product revenue was $19.7 million in Q1 2025, down from $25.6 million in Q1 2024, due to increased competition from oral products.
• Research and development expenses increased slightly to $86.4 million in Q1 2025 from $84.7 million in Q1 2024.
• Selling, general, and administrative expenses decreased slightly to $129.3 million in Q1 2025 from $129.5 million in Q1 2024.
• The company submitted an sNDA to the FDA for EMPAVELI in early 2025 for C3G and IC-MPGN, with Priority Review granted and a PDUFA date of July 28, 2025.
• Apellis plans to initiate two registrational clinical trials with EMPAVELI in the second half of 2025 for FSGS and DGF.
• Cash and cash equivalents were $358.4 million as of March 31, 2025.
• The company believes its current cash and cash equivalents, combined with anticipated revenue from EMPAVELI and SYFOVRE sales, will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive developments such as the FDA Priority Review and planned clinical trials, the decreased sales and increased net loss temper the outlook.

Positives

• The FDA granted Priority Review for EMPAVELI's sNDA for C3G and IC-MPGN, indicating a potentially faster approval process.
• Apellis is advancing its pipeline with plans to initiate a Phase 2 trial for SYFOVRE treatment with APL-3007 in GA patients in Q2 2025.
• The company is planning two registrational clinical trials with EMPAVELI in the second half of 2025 for FSGS and DGF, expanding its potential market.
• The company believes its current cash resources and anticipated revenues to fund operations for at least the next 12 months, providing financial stability.
• Sobi received validation for its indication extension application for C3G and IC-MPGN from the European Medicines Agency, or EMA.

Negatives

• Apellis Pharmaceuticals' Q1 2025 net loss increased to $92.2 million from $66.4 million year-over-year, indicating increased financial strain.
• SYFOVRE sales decreased to $130.2 million in Q1 2025, primarily due to increased rebates, impacting revenue.
• EMPAVELI sales decreased to $19.7 million in Q1 2025 due to competition from oral products, reducing market share.
• Total revenue decreased by 3% to $166.8 million in Q1 2025 from $172.3 million in Q1 2024.

Risks

• Increased rebates are negatively impacting SYFOVRE revenue.
• Competition from oral products is reducing EMPAVELI sales.
• The company is incurring significant net operating losses and expects to continue to do so.
• The successful development and commercialization of product candidates are subject to numerous risks and uncertainties.
• The company may need additional capital resources to fund its operating plans and capital expenditure requirements.
• The company is subject to restrictions on sales and licensing transactions with respect to its core intellectual property.

Future Outlook

Apellis expects its current cash and cash equivalents, combined with anticipated revenue from EMPAVELI and SYFOVRE sales, will be sufficient to fund operations for at least the next 12 months. The company plans to continue developing systemic pegcetacoplan and focus research initiatives on high-potential opportunities.

Management Comments

• The company is devoting substantial resources to the commercial infrastructure for SYFOVRE for GA.
• The company is also devoting substantial resources to the development of our product candidates.

Industry Context

Apellis is operating in a competitive biopharmaceutical market, particularly in the PNH space where EMPAVELI faces increasing competition from oral therapies. The company is focusing on expanding the indications for its existing products and developing new product candidates to maintain its competitive edge.

Comparison to Industry Standards

• Comparing Apellis to companies like Regeneron (EYLEA) and Roche (Vabysmo) in the AMD market, SYFOVRE's sales trajectory is being closely watched.
• The increased rebates impacting SYFOVRE sales are a common challenge in the pharmaceutical industry, requiring effective pricing and market access strategies.
• The competition EMPAVELI faces from oral therapies in PNH mirrors trends in other therapeutic areas where oral alternatives are preferred for convenience.
• Apellis's R&D spending as a percentage of revenue is typical for a biotech company focused on clinical development and new indications.

Management Changes

Legal Proceedings

• The securities class action lawsuit was dismissed with prejudice on March 17, 2025, but the plaintiffs have filed an appeal.
• The stockholder derivative litigation is stayed pending the ruling on the motion to dismiss in the securities class action.
• An individual filed a civil action against the Company in August 2024, alleging personal injury claims in connection with the use of SYFOVRE; the motion to dismiss is pending.

Stakeholder Impact

• Shareholders may be concerned about the decreased sales and increased net loss.
• Employees may be affected by the company's cost-cutting measures and restructuring efforts.
• Patients may benefit from the company's continued development of new therapies.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• Submit a supplemental new drug application, or sNDA, to the FDA in early 2025, following the positive results from the Phase 3 VALIANT trial investigating systemic pegcetacoplan in adolescent and adult patients with naive and post-transplant recurrence C3G and IC-MPGN that we reported in August 2024.
• Initiate a Phase 2 multi-dose trial in patients with GA in the second quarter of 2025.
• Initiate two registrational clinical trials with EMPAVELI in the second half of 2025 for the treatment of primary focal segmental glomerulosclerosis, or FSGS, and delayed graft function, or DGF.

Key Dates

Keywords

SYFOVRE, EMPAVELI, Apellis Pharmaceuticals, Financial Results, C3G, IC-MPGN, Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria, Revenue, Clinical Trials